Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Centre, Training and Research Hospital, Istanbul, Turkey.
Kardiol Pol. 2017;75(4):351-359. doi: 10.5603/KP.a2016.0185. Epub 2017 Feb 2.
Obstructive sleep apnoea syndrome (OSAS) is reported to be associated with hypertension, coronary artery disease, atrial fibrillation, and heart failure. Galectin-3 plays an important role in the regulation of inflammation, development of cardiac fibrosis, and remodelling. A significant relationship between galectin-3 and the total number of coronary plaques and the macrocalcified plaque structures of patients with type 2 diabetes mellitus has been reported.
The aim of this study was to investigate the association between galectin-3 level and coronary plaque burden as well as OSAS severity in patients with OSAS.
A total of 87 consecutive patients with a diagnosis of OSAS and 21 age- and gender-matched control subjects were recruited for the present study. The patients with OSAS were also categorised according to their apnoea hypopnoea index (AHI) as follows: mild (AHI = 5-15), moderate (AHI = 15-30), and severe (AHI > 30). All study subjects underwent coronary computed tomography angiography to detect coronary atherosclerosis. Also, all participants of serum galectin-3 concentrations were measured.
Mean galectin-3 level was significantly higher in patients with OSAS compared to control subjects (p < 0.001) and in the severe OSAS group, compared to the moderate and mild OSAS groups (p < 0.001). Correlation analysis indicated significant positive relationships between galectin-3 concentrations and the total number of coronary plaques (p < 0.001), high-sensitivity C-reactive protein (p = 0.001), and severity of OSAS (p < 0.001). In multivariate analysis, galectin-3 (p = 0.01) and age (p = 0.025) were significant independent predictors of coronary atherosclerosis, after adjusting for other risk factors. Also, it has been found that galectin-3 concentration is a predictor of OSAS severity (p = 0.001).
Galectin-3 is associated with coronary atherosclerosis and OSAS severity in OSAS patients.
阻塞性睡眠呼吸暂停综合征（OSAS）与高血压、冠状动脉疾病、心房颤动和心力衰竭有关。半乳糖凝集素-3在炎症调节、心脏纤维化发展和重塑中发挥重要作用。已经报道了半乳糖凝集素-3与 2 型糖尿病患者的总冠状动脉斑块数量和大钙化斑块结构之间存在显著关系。
本研究旨在探讨半乳糖凝集素-3水平与 OSAS 患者冠状动脉斑块负担和 OSAS 严重程度之间的关系。
本研究共纳入 87 例确诊为 OSAS 的连续患者和 21 名年龄和性别匹配的对照组。根据呼吸暂停低通气指数（AHI）将 OSAS 患者分为轻度（AHI=5-15）、中度（AHI=15-30）和重度（AHI>30）。所有研究对象均接受冠状动脉计算机断层血管造影术以检测冠状动脉粥样硬化。同时，测量所有参与者的血清半乳糖凝集素-3 浓度。
与对照组相比，OSAS 患者的平均半乳糖凝集素-3 水平显着升高（p<0.001），且重度 OSAS 组显着高于中度和轻度 OSAS 组（p<0.001）。相关分析表明，半乳糖凝集素-3 浓度与冠状动脉总斑块数量呈显著正相关（p<0.001）、超敏 C 反应蛋白（p=0.001）和 OSAS 严重程度呈正相关（p<0.001）。在多变量分析中，调整其他危险因素后，半乳糖凝集素-3（p=0.01）和年龄（p=0.025）是冠状动脉粥样硬化的独立显著预测因子。此外，还发现半乳糖凝集素-3 浓度是 OSAS 严重程度的预测因子（p=0.001）。
半乳糖凝集素-3与 OSAS 患者的冠状动脉粥样硬化和 OSAS 严重程度有关。
